{"id":24529,"date":"2022-05-30T10:21:20","date_gmt":"2022-05-30T09:21:20","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=24529"},"modified":"2022-05-30T10:21:25","modified_gmt":"2022-05-30T09:21:25","slug":"pfizer-launches-an-accord-for-a-healthier-world-to-improve-health-equity-for-1-2-billion-people-living-in-45-lower-income-countries","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/pfizer-launches-an-accord-for-a-healthier-world-to-improve-health-equity-for-1-2-billion-people-living-in-45-lower-income-countries\/","title":{"rendered":"Pfizer Launches \u2018An Accord for a Healthier World\u2019 to Improve Health Equity for 1.2 Billion People Living in 45 Lower-Income Countries"},"content":{"rendered":"\n<p>Published on <a href=\"https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-launches-accord-healthier-world-improve-health?utm_medium=email&amp;_hsmi=214326803&amp;_hsenc=p2ANqtz-9gtCYaOuaEV7Ym9GTjJZuopkwYrzOVOHGEbdCwGk7_TbHb7slDIWdgz3xQOAHAk-1ZmUU8dDR6OhuBCmcOlT7EQUJvzg&amp;utm_content=214326803&amp;utm_source=hs_email\" target=\"_blank\" rel=\"noreferrer noopener\">PFIZER website<\/a> on May 25, 2022<\/p>\n\n\n\n<ul><li><em>Pfizer will provide all its current and future patent-protected medicines and vaccines available in the U.S. or EU on a not-for-profit basis to 45 lower-income countries.<\/em><\/li><li><em>Rwanda, Ghana, Malawi, Senegal and Uganda are the first five countries to commit to join the Accord. Health officials in these countries will help identify and resolve hurdles beyond supply to inform the roll out in all 45 lower-income countries.<\/em><\/li><li><em>Pfizer calls upon global health leaders and organizations to join the Accord, bringing their expertise and resources to close the health equity gap and help create a healthier world for 1.2 billion people.<\/em><\/li><\/ul>\n\n\n\n<p><a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pfizer.com%2F&amp;esheet=52729323&amp;newsitemid=20220525005109&amp;lan=en-US&amp;anchor=Pfizer+Inc.&amp;index=1&amp;md5=8fe9b0ee2c39d4bc4ee17bf8d8bcd68e\" target=\"_blank\" rel=\"noreferrer noopener\">Pfizer Inc.<\/a>\u00a0(NYSE: PFE) today launched \u2018An Accord for a Healthier World.\u2019 This groundbreaking initiative aims to provide all of Pfizer\u2019s patented, high-quality medicines and vaccines available in the U.S. or the European Union on a not-for-profit basis to 1.2 billion people in 45 lower-income countries. The Accord seeks to greatly reduce the health inequities that exist between many lower-income countries and the rest of the world.<\/p>\n\n\n\n<p>\u201cAs we learned in the global COVID-19 vaccine rollout, supply is only the first step to helping patients. We will work closely with global health leaders to make improvements in diagnosis, education, infrastructure, storage and more. Only when all the obstacles are overcome can we end healthcare inequities and deliver for all patients,\u201d said Pfizer Chairman and Chief Executive Officer Albert Bourla.<\/p>\n\n\n\n<p>The Accord countries include all 27 low-income countries as well as 18 lower-middle-income countries that have transitioned from low to lower-middle-income classification in the last ten years. Pfizer will work with healthcare officials in Rwanda, Ghana, Malawi, Senegal and Uganda to identify early insights and opportunities to ensure all medicines and vaccines can reach those in need. This will include expertise to support diagnosis, healthcare professional education and training along with supply chain management and other infrastructure enhancements. Learnings from these five countries will be applied to support the roll out for the remaining forty countries.<\/p>\n\n\n\n<p>Pfizer will also collaborate with Accord participants to identify quick and efficient regulatory pathways and procurement processes to reduce the longer amount of time it can take to make new medicines and vaccines available in these countries.<\/p>\n\n\n\n<p>Under the Accord, Pfizer has committed to provide 23 medicines and vaccines that treat infectious diseases, certain cancers, and rare and inflammatory diseases. Making these medicines and vaccines more readily available has the potential to treat non-communicable and infectious diseases that claim the lives of nearly one million people each year in these countries and chronic diseases that significantly impact quality of life for at least half a million more<sup>1<\/sup>. As Pfizer launches new medicines and vaccines, those products will also be included in the Accord portfolio on a not-for-profit basis.<\/p>\n\n\n\n<p>The Accord also aims to establish faster access to Pfizer\u2019s future pipeline medicines and vaccines on a not-for-profit-basis to the 45 countries, particularly those that treat diseases that disproportionately impact global health. To further this commitment, Pfizer, with funding from the Bill &amp; Melinda Gates Foundation, is advancing work on the development of vaccine candidates for the prevention of Group B Streptococcus (GBS), which is a leading cause of stillbirth and newborn mortality in low-income countries. They are also discussing opportunities to support Respiratory Syncytial Virus (RSV) vaccine development, another maternal vaccine.<\/p>\n\n\n\n<p>\u201cEveryone, no matter where they live, should have the same access to innovative, life-saving drugs and vaccines,\u201d said Bill Gates, Co-Chair of the Bill &amp; Melinda Gates Foundation. \u201cThe Accord for a Healthier World could help millions more people in low-income countries get the tools they need to live a healthy life. Pfizer is setting an example for other companies to follow.\u201d<\/p>\n\n\n\n<p>&#8220;Rapid and affordable access to the most advanced medicines and vaccines is the cornerstone of global health equity. Pfizer\u2019s commitment under the Accord program sets a new standard in this regard. Combined with additional investments in strengthening Africa\u2019s public health systems and pharmaceutical regulators, the Accord is an important step toward sustainable health security for countries at every income level,\u201d said His Excellency Paul Kagame, President of Rwanda.<\/p>\n\n\n\n<p>&#8220;We must continue to strive for quality healthcare for all people to live longer, stronger and healthier lives,&#8221; said His Excellency President Nana Addo Dankwa Akufo-Addo, President of Ghana. &#8220;It will require strong cooperation between the public and private sectors. We are proud to join this Accord to work together on this important goal.&#8221;<\/p>\n\n\n\n<p>\u201cSenegal proudly supports the launch of An Accord for a Healthier World to improve health equity and outcomes for the people of our country and across the world,\u201d said His Excellency Macky Sall, President of Senegal. \u201cTogether, we will work for a better world.\u201d<\/p>\n\n\n\n<p>&#8220;The great thing about this Accord is that it helps low-income countries without violating their dignity and agency as people, for it is a true partnership that involves both Pfizer and countries like Malawi sharing the burden of costs and tasks in the production and delivery of supplies that will save millions of lives. This is how all global problems should be tackled,\u201d said His Excellency Lazarus Chakwera, President of Malawi.<\/p>\n\n\n\n<p>&#8220;It is the time to close the health equity gap,&#8221; said His Excellency Yoweri Museveni, President of Uganda. \u201cUganda is proud to join the Accord, and we are committed to working with Pfizer and all Accord partners to find new ways to address access challenges.&#8221;<\/p>\n\n\n\n<p>Further details about An Accord for a Healthier World are available at\u00a0<a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.pfizer.com%2FAccord&amp;esheet=52729323&amp;newsitemid=20220525005109&amp;lan=en-US&amp;anchor=Pfizer.com%2FAccord&amp;index=2&amp;md5=08ece34fdd0c9790f5871b1062ffa670\" target=\"_blank\" rel=\"noreferrer noopener\">Pfizer.com\/Accord<\/a>.<\/p>\n\n\n\n<p><sup>1<\/sup>\u00a0Internal calculations based on data collected via\u00a0<a rel=\"noreferrer noopener\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fvizhub.healthdata.org%2Fgbd-compare%2F&amp;esheet=52729323&amp;newsitemid=20220525005109&amp;lan=en-US&amp;anchor=https%3A%2F%2Fvizhub.healthdata.org%2Fgbd-compare%2F&amp;index=12&amp;md5=1c277e204d4d6bc9a5df617bd1f6bd50\" target=\"_blank\">https:\/\/vizhub.healthdata.org\/gbd-compare\/\u00a0<\/a><br><sup>2<\/sup><a rel=\"noreferrer noopener\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gavi.org%2Ftypes-support%2Fsustainability%2Feligibility&amp;esheet=52729323&amp;newsitemid=20220525005109&amp;lan=en-US&amp;anchor=Eligibility+%28gavi.org%29&amp;index=13&amp;md5=7810493a4c6eade2ce46e86da4183b1e\" target=\"_blank\"> Eligibility (<\/a><a href=\"http:\/\/gavi.org\/\" target=\"_blank\" rel=\"noreferrer noopener\">gavi.org<\/a>)<\/p>\n\n\n\n<p>Media Contact:<br><a href=\"mailto:PfizerMediaRelations@pfizer.com\" target=\"_blank\" rel=\"noreferrer noopener\">PfizerMediaRelations@pfizer.com\u00a0<\/a><br>+1 (212) 733-1226<\/p>\n\n\n\n<p>Investor Contact:<br><a href=\"mailto:IR@Pfizer.com\" target=\"_blank\" rel=\"noreferrer noopener\">IR@Pfizer.com\u00a0<\/a><br>+1 (212) 733-4848<\/p>\n\n\n\n<p>Source: Pfizer Inc.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Published on PFIZER website on May 25, 2022 Pfizer will provide all its current and future patent-protected medicines and vaccines available in the U.S. or EU on a not-for-profit basis to 45 lower-income countries. Rwanda, Ghana, Malawi, Senegal and Uganda are the first five countries to commit to join the Accord. Health officials in these [&hellip;]<\/p>\n","protected":false},"author":139,"featured_media":24539,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[31],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pfizer Launches \u2018An Accord for a Healthier World\u2019 to Improve Health Equity for 1.2 Billion People Living in 45 Lower-Income Countries - French\u00a0National ANTIBIOTIC RESISTANCE Portal<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/pfizer-launches-an-accord-for-a-healthier-world-to-improve-health-equity-for-1-2-billion-people-living-in-45-lower-income-countries\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer Launches \u2018An Accord for a Healthier World\u2019 to Improve Health Equity for 1.2 Billion People Living in 45 Lower-Income Countries - French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/pfizer-launches-an-accord-for-a-healthier-world-to-improve-health-equity-for-1-2-billion-people-living-in-45-lower-income-countries\/\" \/>\n<meta property=\"og:site_name\" content=\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-30T09:21:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-05-30T09:21:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/05\/Aide-soutien.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"489\" \/>\n\t<meta property=\"og:image:height\" content=\"489\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u00c9milie Noguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u00c9milie Noguez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/pfizer-launches-an-accord-for-a-healthier-world-to-improve-health-equity-for-1-2-billion-people-living-in-45-lower-income-countries\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/pfizer-launches-an-accord-for-a-healthier-world-to-improve-health-equity-for-1-2-billion-people-living-in-45-lower-income-countries\/\"},\"author\":{\"name\":\"\u00c9milie Noguez\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\"},\"headline\":\"Pfizer Launches \u2018An Accord for a Healthier World\u2019 to Improve Health Equity for 1.2 Billion People Living in 45 Lower-Income Countries\",\"datePublished\":\"2022-05-30T09:21:20+00:00\",\"dateModified\":\"2022-05-30T09:21:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/pfizer-launches-an-accord-for-a-healthier-world-to-improve-health-equity-for-1-2-billion-people-living-in-45-lower-income-countries\/\"},\"wordCount\":955,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/pfizer-launches-an-accord-for-a-healthier-world-to-improve-health-equity-for-1-2-billion-people-living-in-45-lower-income-countries\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/05\/Aide-soutien.jpg\",\"articleSection\":[\"Actualit\u00e9s\"],\"inLanguage\":\"en-GB\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/pfizer-launches-an-accord-for-a-healthier-world-to-improve-health-equity-for-1-2-billion-people-living-in-45-lower-income-countries\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/pfizer-launches-an-accord-for-a-healthier-world-to-improve-health-equity-for-1-2-billion-people-living-in-45-lower-income-countries\/\",\"name\":\"Pfizer Launches \u2018An Accord for a Healthier World\u2019 to Improve Health Equity for 1.2 Billion People Living in 45 Lower-Income Countries - French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/pfizer-launches-an-accord-for-a-healthier-world-to-improve-health-equity-for-1-2-billion-people-living-in-45-lower-income-countries\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/pfizer-launches-an-accord-for-a-healthier-world-to-improve-health-equity-for-1-2-billion-people-living-in-45-lower-income-countries\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/05\/Aide-soutien.jpg\",\"datePublished\":\"2022-05-30T09:21:20+00:00\",\"dateModified\":\"2022-05-30T09:21:25+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/pfizer-launches-an-accord-for-a-healthier-world-to-improve-health-equity-for-1-2-billion-people-living-in-45-lower-income-countries\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/pfizer-launches-an-accord-for-a-healthier-world-to-improve-health-equity-for-1-2-billion-people-living-in-45-lower-income-countries\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/pfizer-launches-an-accord-for-a-healthier-world-to-improve-health-equity-for-1-2-billion-people-living-in-45-lower-income-countries\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/05\/Aide-soutien.jpg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/05\/Aide-soutien.jpg\",\"width\":489,\"height\":489,\"caption\":\"Cr\u00e9dit : Pixabay\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/pfizer-launches-an-accord-for-a-healthier-world-to-improve-health-equity-for-1-2-billion-people-living-in-45-lower-income-countries\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Practical info &amp; communications\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"News\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Pfizer Launches \u2018An Accord for a Healthier World\u2019 to Improve Health Equity for 1.2 Billion People Living in 45 Lower-Income Countries\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"name\":\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"description\":\"INSERM - From science to health\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\",\"name\":\"\u00c9milie Noguez\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pfizer Launches \u2018An Accord for a Healthier World\u2019 to Improve Health Equity for 1.2 Billion People Living in 45 Lower-Income Countries - French\u00a0National ANTIBIOTIC RESISTANCE Portal","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/pfizer-launches-an-accord-for-a-healthier-world-to-improve-health-equity-for-1-2-billion-people-living-in-45-lower-income-countries\/","og_locale":"en_GB","og_type":"article","og_title":"Pfizer Launches \u2018An Accord for a Healthier World\u2019 to Improve Health Equity for 1.2 Billion People Living in 45 Lower-Income Countries - French\u00a0National ANTIBIOTIC RESISTANCE Portal","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/pfizer-launches-an-accord-for-a-healthier-world-to-improve-health-equity-for-1-2-billion-people-living-in-45-lower-income-countries\/","og_site_name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","article_published_time":"2022-05-30T09:21:20+00:00","article_modified_time":"2022-05-30T09:21:25+00:00","og_image":[{"width":489,"height":489,"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/05\/Aide-soutien.jpg","type":"image\/jpeg"}],"author":"\u00c9milie Noguez","twitter_card":"summary_large_image","twitter_misc":{"Written by":"\u00c9milie Noguez","Estimated reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/pfizer-launches-an-accord-for-a-healthier-world-to-improve-health-equity-for-1-2-billion-people-living-in-45-lower-income-countries\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/pfizer-launches-an-accord-for-a-healthier-world-to-improve-health-equity-for-1-2-billion-people-living-in-45-lower-income-countries\/"},"author":{"name":"\u00c9milie Noguez","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3"},"headline":"Pfizer Launches \u2018An Accord for a Healthier World\u2019 to Improve Health Equity for 1.2 Billion People Living in 45 Lower-Income Countries","datePublished":"2022-05-30T09:21:20+00:00","dateModified":"2022-05-30T09:21:25+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/pfizer-launches-an-accord-for-a-healthier-world-to-improve-health-equity-for-1-2-billion-people-living-in-45-lower-income-countries\/"},"wordCount":955,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/pfizer-launches-an-accord-for-a-healthier-world-to-improve-health-equity-for-1-2-billion-people-living-in-45-lower-income-countries\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/05\/Aide-soutien.jpg","articleSection":["Actualit\u00e9s"],"inLanguage":"en-GB"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/pfizer-launches-an-accord-for-a-healthier-world-to-improve-health-equity-for-1-2-billion-people-living-in-45-lower-income-countries\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/pfizer-launches-an-accord-for-a-healthier-world-to-improve-health-equity-for-1-2-billion-people-living-in-45-lower-income-countries\/","name":"Pfizer Launches \u2018An Accord for a Healthier World\u2019 to Improve Health Equity for 1.2 Billion People Living in 45 Lower-Income Countries - French\u00a0National ANTIBIOTIC RESISTANCE Portal","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/pfizer-launches-an-accord-for-a-healthier-world-to-improve-health-equity-for-1-2-billion-people-living-in-45-lower-income-countries\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/pfizer-launches-an-accord-for-a-healthier-world-to-improve-health-equity-for-1-2-billion-people-living-in-45-lower-income-countries\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/05\/Aide-soutien.jpg","datePublished":"2022-05-30T09:21:20+00:00","dateModified":"2022-05-30T09:21:25+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/pfizer-launches-an-accord-for-a-healthier-world-to-improve-health-equity-for-1-2-billion-people-living-in-45-lower-income-countries\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/pfizer-launches-an-accord-for-a-healthier-world-to-improve-health-equity-for-1-2-billion-people-living-in-45-lower-income-countries\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/pfizer-launches-an-accord-for-a-healthier-world-to-improve-health-equity-for-1-2-billion-people-living-in-45-lower-income-countries\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/05\/Aide-soutien.jpg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/05\/Aide-soutien.jpg","width":489,"height":489,"caption":"Cr\u00e9dit : Pixabay"},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/pfizer-launches-an-accord-for-a-healthier-world-to-improve-health-equity-for-1-2-billion-people-living-in-45-lower-income-countries\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Practical info &amp; communications","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/"},{"@type":"ListItem","position":3,"name":"News","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/"},{"@type":"ListItem","position":4,"name":"Pfizer Launches \u2018An Accord for a Healthier World\u2019 to Improve Health Equity for 1.2 Billion People Living in 45 Lower-Income Countries"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","description":"INSERM - From science to health","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3","name":"\u00c9milie Noguez"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-11 06:29:35","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/24529"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/users\/139"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/comments?post=24529"}],"version-history":[{"count":9,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/24529\/revisions"}],"predecessor-version":[{"id":24551,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/24529\/revisions\/24551"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/media\/24539"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/media?parent=24529"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/categories?post=24529"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/tags?post=24529"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}